Not Yet Recruiting PHASE2 INTERVENTIONAL 1-arm
NCT07279584
Golidocitinib Combined With GemOx in RR PTCL
An Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Golidocitinib Combined With GemOx in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma
Sponsor: Ruijin Hospital
Conditions
Peripheral T-cell Lymphomas (PTCL)
Interventions
GEMOX golidocitinib
Updated 1 time since 2026 Last updated: Dec 1, 2025 Started: Dec 20, 2025 Primary completion: Dec 31, 2026 Completion: Dec 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE2 trial investigates Peripheral T-cell Lymphomas (PTCL) and is currently actively recruiting participants. Ruijin Hospital leads this study, which shows 1 recorded version since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Ruijin Hospital
Data source: Ruijin Hospital
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.